Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Akeso, Inc. (9926.HK)
Zhongshan, CN
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.97% | +1.81% | -13.03% | +10.48% | -3.91% | +4.51% | +40.93% | +239.86% | +82.68% | +386.01% | +386.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 17 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+40.2% ★ Q4'25: +90.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-100.0% Q4'25: +1.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-53.7% Q4'25: -70.4% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-29.6% Q4'25: -29.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-20.3% Q4'25: -44.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+6.1% Q4'25: +8.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.18× Q4'25: -2.37× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 13 EPS Ana. |
Dec 2027 16 Rev. Ana. 15 EPS Ana. |
Dec 2028 14 Rev. Ana. 12 EPS Ana. |
Dec 2029 9 Rev. Ana. 10 EPS Ana. |
Dec 2030 13 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 25.68M (-100.0%)
|
225.63M
est: 510.79M (-55.8%)
|
837.66M
est: 869.36M (-3.6%)
|
4.53B
est: 1.74B (+159.6%)
|
2.12B
est: 2.45B (-13.5%)
|
2.98B
est: 3.35B (-11.1%)
|
5.17B
4.50B – 6.88B
+54.5% YoY
|
7.73B
6.01B – 10.87B
+49.5% YoY
|
10.90B
8.88B – 14.99B
+41.1% YoY
|
18.05B
14.72B – 24.83B
+65.6% YoY
|
24.47B
19.95B – 33.66B
+35.6% YoY
|
| EBITDA |
-1.01B
est: -4.13M (-24,280.9%)
|
-1.32B
est: -82.23M (-1,500.8%)
|
-1.27B
est: -139.95M (-809.7%)
|
2.17B
est: -732.40M (+396.6%)
|
-604.99M
est: -1.03B (+41.3%)
|
-880.31M
est: -1.41B (+37.4%)
|
-2.17B
-2.89B – -1.89B
-54.5% YoY
|
-3.25B
-4.57B – -2.52B
-49.5% YoY
|
-4.58B
-6.30B – -3.73B
-41.1% YoY
|
-7.59B
-10.43B – -6.18B
-65.6% YoY
|
-10.28B
-14.14B – -8.38B
-35.6% YoY
|
| EBIT |
-1.02B
est: -4.60M (-22,155.3%)
|
-1.36B
est: -91.48M (-1,391.1%)
|
-1.38B
est: -155.69M (-785.7%)
|
2.03B
est: -763.97M (+365.7%)
|
-730.31M
est: -1.08B (+32.1%)
|
-880.31M
est: -1.47B (+40.0%)
|
-2.27B
-3.01B – -1.97B
-54.5% YoY
|
-3.39B
-4.76B – -2.63B
-49.5% YoY
|
-4.78B
-6.57B – -3.89B
-41.1% YoY
|
-7.91B
-10.88B – -6.45B
-65.6% YoY
|
-10.73B
-14.75B – -8.74B
-35.6% YoY
|
| Net Income |
-1.04B
est: -1.06B (+1.8%)
|
-1.07B
est: -910.25M (-18.1%)
|
-1.17B
est: -1.17B (+0.5%)
|
2.03B
est: -684.01M (+396.5%)
|
-514.52M
est: -524.66M (+1.9%)
|
-1.08B
est: -999.72M (-8.5%)
|
111.45M
37.43M – 224.88M
+111.1% YoY
|
1.14B
694.98M – 2.06B
+923.1% YoY
|
2.31B
1.34B – 4.93B
+102.7% YoY
|
6.80B
5.17B – 10.12B
+194.5% YoY
|
10.03B
7.62B – 14.92B
+47.4% YoY
|
| SGA |
253.03M
est: 23.52M (+975.8%)
|
422.67M
est: 467.79M (-9.6%)
|
751.67M
est: 796.18M (-5.6%)
|
1.09B
est: 1.45B (-24.6%)
|
1.21B
est: 2.03B (-40.8%)
|
1.69B
est: 2.78B (-39.2%)
|
4.29B
3.73B – 5.70B
+54.5% YoY
|
6.41B
4.98B – 9.01B
+49.5% YoY
|
9.04B
7.37B – 12.43B
+41.1% YoY
|
14.97B
12.20B – 20.59B
+65.6% YoY
|
20.29B
16.54B – 27.91B
+35.6% YoY
|
| EPS |
-1.65
est: -1.24 (-33.0%)
|
-1.32
est: -1.07 (-23.4%)
|
-1.42
est: -1.26 (-12.3%)
|
2.42
est: -0.81 (+397.6%)
|
-0.60
est: -0.52 (-16.0%)
|
-1.20
est: -0.41 (-190.0%)
|
0.13
0.04 – 0.25
+130.2% YoY
|
1.34
0.77 – 2.28
+970.0% YoY
|
3.04
1.48 – 5.47
+127.3% YoY
|
7.54
5.72 – 11.21
+147.9% YoY
|
11.11
8.44 – 16.52
+47.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yu Xia | Founder, Chief Executive Officer, President & Chairwoman | 6M | male |
| Xinfeng Zhang | Senior Vice President | 5M | — |
| Jing Min | Senior Vice President | 5M | — |
| Mingxiu Hu | Senior Vice President | 5M | — |
| Baiyong Li | Co-Founder, Executive Vice President, CSO & Executive Director | 5M | — |
| Zhongmin Wang | Co-Founder, Senior Vice President & Executive Director | 4M | male |
| Peng Zhang | Co-Founder, Senior Vice President & Executive Director | 4M | — |
| Yong Guo | Senior Vice President & Chief Commercial Officer | — | male |
| Wai Yan Leung | Company Secretary | — | female |
| Bing C. Wang | Chief Financial Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9926.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
